On the other hand, β-endorphin, a cleavage product of pro-opiomelanocortin (POMC), is an endogenous µ-opioid polypeptide primarily produced by the hypothalamus. POMC neuronal cell bodies are primarily localized in the arcuate nucleus (ARC) of the hypothalamus. The terminals of these POMC neurons are distributed throughout the CNS, including the paraventricular nucleus (PVN) of the hypothalamus, which is an important area of the brain to the stress response of the hypothalamicpituitary-adrenal (HPA) axis. Therefore, β-endorphin released by the activation of the hypothalamic POMC neuron is believed to change innate immune function. In this study, we investigated the role of hypothalamic µ-opioidergic systems in anti-tumor immune responses using the designer receptors exclusively activated by designer drugs (DREADD) system. To perform the activation of hypothalamic POMC neurons, we generated the transgenic mice expressing Gq-coupled human muscarinic M3 DREADD (hM3Dq) protein under the control of the POMC promoter in the hypothalamus. The hM3Dq was activated by a designer drug, clozapine N-oxide (CNO). Under these conditions, CNO-induced activation of hypothalamic POMC neurons significantly suppressed tumor growth in tumor-bearing mice. This suppression of tumor growth induced by the activation of hypothalamic POMC neurons by the administration of CNO was reversed by the pre-microinjection of naloxone into the PVN. Furthermore, CNO-induced activation of hypothalamic POMC neurons significantly decreased the plasma level of corticosterone and increased the number of NK cells in the spleen. These findings suggest that β-endorphin released by the activation of hypothalamic POMC neurons may suppress tumor growth via the PVN µ-opioid receptor-mediated suppression of the stress response of the HPA axis and the activation of cell-mediated immunity associated with NK cell activation.
omelanocortin (POMC), is an endogenous µ-opioid polypeptide primarily produced by the hypothalamus. POMC neuronal cell bodies are primarily localized in the arcuate nucleus (ARC) of the hypothalamus. The terminals of these POMC neurons are distributed throughout the CNS, including the paraventricular nucleus (PVN) of the hypothalamus, which is an important area of the brain to the stress response of the hypothalamicpituitary-adrenal (HPA) axis. Therefore, β-endorphin released by the activation of the hypothalamic POMC neuron is believed to change innate immune function. In this study, we investigated the role of hypothalamic µ-opioidergic systems in anti-tumor immune responses using the designer receptors exclusively activated by designer drugs (DREADD) system. To perform the activation of hypothalamic POMC neurons, we generated the transgenic mice expressing Gq-coupled human muscarinic M3 DREADD (hM3Dq) protein under the control of the POMC promoter in the hypothalamus. The hM3Dq was activated by a designer drug, clozapine N-oxide (CNO). Under these conditions, CNO-induced activation of hypothalamic POMC neurons significantly suppressed tumor growth in tumor-bearing mice. This suppression of tumor growth induced by the activation of hypothalamic POMC neurons by the administration of CNO was reversed by the pre-microinjection of naloxone into the PVN. Furthermore, CNO-induced activation of hypothalamic POMC neurons significantly decreased the plasma level of corticosterone and increased the number of NK cells in the spleen. These findings suggest that β-endorphin released by the activation of hypothalamic POMC neurons may suppress tumor growth via the PVN µ-opioid receptor-mediated suppression of the stress response of the HPA axis and the activation of cell-mediated immunity associated with NK cell activation.
PS14
Gender specific gene-by-environment interaction effects of SLC6A4 polymorphism and childhood maltreatment on anxiety sensitivity Abstract Purposes: Anxiety sensitivity (AS) is a well-established characteristic that predisposes to the development of panic attack and several anxiety disorders. It has been suggested that AS is interactively influenced by genetic and environmental factors such as childhood maltreatment. Serotonin transporter gene (SLC6A4) promoter polymorphism (5-HTTLPR) is regarded as a strong candidate genetic factor for AS. The aim of this study is to examine the effect of childhood maltreatment and SLC6A4 polymorphism, and their interaction on AS by gender. Methods: Participants were 139 women and 77 men recruited from undergraduate psychology students. They were requested to genotyped for the SLC6A4 polymorphism and complete the measures for AS, Connor Davidson Resilience scale (CDRS) and childhood trauma questionnaire (CTQ). We classified the SLC6A4 polymorphism into the three functional triallelic genotypes: La/La; La/Lg or La/S; and Lg/Lg or Lg/S or S/S. The interaction and main effects of SLC6A4 polymorphism and childhood maltreatment on AS were analyzed by general linear models in all subjects and then in gender-stratified groups. All of the analyses were repeated using the classical biallelic classification without separating Lg from La Results: High AS score was observed in female gender and participants with childhood maltreatment. In GLM analysis for AS in total subjects, there were significant main effects of gender (p=0.011) and CDRS but interaction effect between SLC6A4 genotype and childhood maltreatment was not observed. However, in separate GLM models by gender, the interaction effect was significant in females (p=0.044) but not in males. In males, there was significant main effect of childhood maltreatment (p=0.039) only. When we perform same analyses using biallelic classification, these gender specific interaction effect were not observed. Conclusions: Our results suggest that there is gender specificity of the effects of the SLC6A4 polymorphism, childhood maltreatment, and their interaction on AS.
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Can gene therapy treat anxiety? -Overexpression of Neuropeptide S using adeno-associated viral vectors Abstract Objective: Anxiety disorders have a lifetime prevalence of almost 30% and pose a huge burden on both patient and society. Available treatment options commonly induce adverse effects, urging the need for novel compounds. Neuropeptide S (NPS) has attracted attention due to its anxiolytic properties in rodents. The present study investigated the impact of NPS overexpression on anxiety-related behavior by infusing a recombinant adeno-associated virus (rAAV) into the medial amygdala. Methods: Using stereotaxic surgery, viral vectors (rAAV-NPS vs. rAAV-Empty) were injected bilaterally into the medial amygdala of male adult Wistar rats using a thin glass micropipette. Behavior was characterized using standard anxiety, locomotion and depression tests (Elevated plus maze (EPM), Light/dark box (LDB), Open field (OF), Forced swim test (FST)). Immunohistochemical stainings were performed to verify overexpression of NPS. Statistical significance of differences between treatment groups was assessed using an independent samples t-test. Results: Results showed that the experimental group (rAAV-NPS) spent significantly more time on the open arm in the EPM paradigm compared to the control group (rAAV-Empty), indicating an anxiolytic effect of NPS (p=.018). Importantly, this anxiolytic effect could be delineated from locomotion, since no treatment differences across conditions were observed in the OF. Similarly, no confounding effects could be found when measuring body weight or depression-related behavior. Histology revealed NPSpositive cells in the medial amygdala in the experimental but not control group, pointing towards successful transduction. Conclusions: This is the first study successfully demonstrating anxiolytic properties of NPS via transgenic overexpression. Our results are largely consistent with studies elucidating the role of NPS in acute treatments, therefore providing evidence for the
